Story perspectives

New Calculator Optimizes Hypertension Treatment; Baxdrostat Shows Promise

9/18/2025

Summary

Story summary

Researchers created the Blood Pressure Treatment Efficacy Calculator, analyzing data from 500 clinical trials to enhance hypertension treatment choices.
The FDA cautions against unauthorized blood pressure devices, highlighting the need for accurate measurements to avoid serious health risks.
The drug baxdrostat shows potential for resistant hypertension, significantly lowering systolic pressure in trials.
AstraZeneca aims for U.S. approval of baxdrostat by late 2025, pending further research on its long-term safety and efficacy.

1 of 1

Story summary

Researchers created the Blood Pressure Treatment Efficacy Calculator, analyzing data from 500 clinical trials to enhance hypertension treatment choices.
The FDA cautions against unauthorized blood pressure devices, highlighting the need for accurate measurements to avoid serious health risks.
The drug baxdrostat shows potential for resistant hypertension, significantly lowering systolic pressure in trials.
AstraZeneca aims for U.S. approval of baxdrostat by late 2025, pending further research on its long-term safety and efficacy.